Payment & Shipping Terms:
|Product Name:||Bremelanotide||Other Name:||PT-141|
|Synonyms:||Bremelanotide; PT 141|
|Unit Size||10 mg/vial|
|Purity:||Greater than 99% as determined by HPLC|
|Appearance:||Filtered white lyophilized (freeze-dried) powder. Each vial contains 10mg of PT-141 Bremelanotide.|
|Usage:||This product is intended for laboratory research use only.|
PT-141 was developed from the Melanotan 2 Peptide. PT-141, commonly known as PT141 or Bremelanotide, is a synthetic heptapeptide analogue of the naturally occuring alpha-Melanocyte stimulating hormone (α-MSH) that is currently being studied for its numerous theoretical therapeutic applications.
PT-141 or Bremelanotide is the generic term for a peptide being studied for its possible use in helping to improve sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). PT-141 has a similar structure to Melanotan-II and is a synthetic analogue of alpha-Melanocyte stimulating hormone (α-MSH). Alpha-MSH is an endogenous peptide that has potential influence over lipid metabolism, appetite, and sexual libido.
Bremelanotide is Palatin’s novel drug candidate for the treatment of male and female sexual dysfunction. First in a new class of therapies called melanocortin agonists, bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular effects found in ED drugs currently available.
PT-141 is a peptide developed from the compound Melanotan 2. Being a metabolite of M2 it lacks the C-Terminal amide found in Melanotan 2. PT-141 works by activating the melanocortin receptors in the nervous system and is being studied as a treatment to sexual dysfunction in men and women.